Literature DB >> 10851064

Pharmaceutical intervention in the JAK/STAT signaling pathway.

H M Seidel1, P Lamb, J Rosen.   

Abstract

Many cytokines exert their effect via the JAK/STAT signal transduction pathway. Due to the medical relevance of many of these cytokines, they are being exploited, either directly, or through antagonists, as therapeutics for a variety of serious diseases. Currently, these therapeutics consist almost entirely of protein products, with all of their attendant drawbacks. Delineation of the signaling mechanisms for the cytokines, however, has allowed the design and implementation of a variety of cell-based and biochemical screens for small molecule mimics or antagonists of these cytokines. Several successful assays will be described along with the advantages of each type of assay. Use of assays of this type should make it possible to discover numerous small molecule cytokine modulators with significant utility in the clinic. Oncogene (2000).

Mesh:

Substances:

Year:  2000        PMID: 10851064     DOI: 10.1038/sj.onc.1203550

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3.

Authors:  Hong Yue; Kuniyoshi Tanaka; Tatsuhiko Furukawa; Sadashiva S Karnik; Wei Li
Journal:  Biochim Biophys Acta       Date:  2012-06-02

Review 2.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

Review 3.  Roles and regulation of stat family transcription factors in human breast cancer.

Authors:  Charles V Clevenger
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 4.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

5.  A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.

Authors:  Theresa Li-Yun Chang; Arevik Mosoian; Richard Pine; Mary E Klotman; John P Moore
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 6.  Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Authors:  Hassan Izzedine; Mark A Perazella
Journal:  Nephrol Dial Transplant       Date:  2015-02-03       Impact factor: 5.992

7.  Expression of Stat3 in feline mammary gland tumours and its relation to histological grade.

Authors:  C Petterino; A Ratto; E Arcicasa; G Podestà; M Drigo; C Pellegrino
Journal:  Vet Res Commun       Date:  2006-08       Impact factor: 2.459

8.  Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells.

Authors:  Frank Schuettauf; David Zurakowski; Kristine Quinto; Meghana A Varde; Dorothea Besch; Alan Laties; Ralph Anderson; Rong Wen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

9.  Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.

Authors:  Can Liu; Yan Zeng; Long-Hai Dai; Tian-Yu Cai; Yue-Ming Zhu; De-Quan Dou; Lan-Qing Ma; Yuan-Xia Sun
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

10.  Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid.

Authors:  Ching-Wen Chen; Yee Chao; Ying-Hsin Chang; Ming-Jen Hsu; Wan-Wan Lin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.